TY - JOUR
T1 - Oral iron therapy
T2 - Current concepts and future prospects for improving efficacy and outcomes
AU - Ebea-Ugwuanyi, Pearl O.
AU - Vidyasagar, Sadasivan
AU - Connor, James R.
AU - Frazer, David M.
AU - Knutson, Mitchell D.
AU - Collins, James F.
N1 - Publisher Copyright:
© 2024 British Society for Haematology and John Wiley & Sons Ltd.
PY - 2024/3
Y1 - 2024/3
N2 - Iron deficiency (ID) and iron-deficiency anaemia (IDA) are global public health concerns, most commonly afflicting children, pregnant women and women of childbearing age. Pathological outcomes of ID include delayed cognitive development in children, adverse pregnancy outcomes and decreased work capacity in adults. IDA is usually treated by oral iron supplementation, typically using iron salts (e.g. FeSO4); however, dosing at several-fold above the RDA may be required due to less efficient absorption. Excess enteral iron causes adverse gastrointestinal side effects, thus reducing compliance, and negatively impacts the gut microbiome. Recent research has sought to identify new iron formulations with better absorption so that lower effective dosing can be utilized. This article outlines emerging research on oral iron supplementation and focuses on molecular mechanisms by which different supplemental forms of iron are transported across the intestinal epithelium and whether these transport pathways are subject to regulation by the iron-regulatory hormone hepcidin.
AB - Iron deficiency (ID) and iron-deficiency anaemia (IDA) are global public health concerns, most commonly afflicting children, pregnant women and women of childbearing age. Pathological outcomes of ID include delayed cognitive development in children, adverse pregnancy outcomes and decreased work capacity in adults. IDA is usually treated by oral iron supplementation, typically using iron salts (e.g. FeSO4); however, dosing at several-fold above the RDA may be required due to less efficient absorption. Excess enteral iron causes adverse gastrointestinal side effects, thus reducing compliance, and negatively impacts the gut microbiome. Recent research has sought to identify new iron formulations with better absorption so that lower effective dosing can be utilized. This article outlines emerging research on oral iron supplementation and focuses on molecular mechanisms by which different supplemental forms of iron are transported across the intestinal epithelium and whether these transport pathways are subject to regulation by the iron-regulatory hormone hepcidin.
UR - http://www.scopus.com/inward/record.url?scp=85182805879&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85182805879&partnerID=8YFLogxK
U2 - 10.1111/bjh.19268
DO - 10.1111/bjh.19268
M3 - Review article
C2 - 38253961
AN - SCOPUS:85182805879
SN - 0007-1048
VL - 204
SP - 759
EP - 773
JO - British Journal of Haematology
JF - British Journal of Haematology
IS - 3
ER -